Nearly every minute, someone in America transitions from normal aging when they occasionally experience senior moments of memory loss to a stage at which their memory loss becomes an everyday part of their life. aMCI is an intermediate stage between normal cognition and Alzheimer's dementia when an older person's memory/cognition is worse than would be expected for his/her age and noticeable to others. This stage is called aMCI, the symptomatic, pre-dementia stage of Alzheimer's disease (AD). Without any therapeutic option, most patients with aMCI (~8 out of 10) face the prognosis of progressing to Alzheimer's dementia within 7 to 10 years, with the associated inability to work, live independently, and eventually loss of basic activities of daily living. No therapy has yet received FDA approval to either treat aMCI symptomatically or to slow the progression of aMCI to Alzheimer's dementia. In this relatively early symptomatic stage of Alzheimer's Disease the brain region associated with memory function, the hippocampus, becomes overactive and this overactivity coincides with memory impairment. AgeneBio is focused on reducing this hippocampal overactivity utilizing compounds which enhance the activity of the GABA-A alpha-5 receptor, a receptor present at high levels in the hippocampus. The GABA-A alpha-5 receptor normally controls the excitability of neurons in this brain region and by boosting its activity it can control the overactivity of this region. AgeneBio is developing compounds that enhance the activity of the GABA-A alpha-5 receptor which have been shown to improve memory function in aged animals with memory impairments.